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Abstract
Phenylketonuria (PKU) is a metabolic disorder caused by impaired phenylalanine hydroxylase (PAH). This condition results in
hyperphenylalaninemia and elevated levels of abnormal phenylalanine metabolites, among which is phenylacetic acid/
phenylacetate (PA). In recent years, PA and its analogs were found to have anticancer activity against a variety of
malignancies suggesting the possibility that PKU may offer protection against cancer through chronically elevated levels of
PA. We tested this hypothesis in a genetic mouse model of PKU (PAH
enu2) which has a biochemical profile that closely
resembles that of human PKU. Plasma levels of phenylalanine in homozygous (HMZ) PAH
enu2 mice were .12-fold those of
heterozygous (HTZ) littermates while tyrosine levels were reduced. Phenylketones, including PA, were also markedly
elevated to the range seen in the human disease. Mice were subjected to 7,12 dimethylbenz[a]anthracene (DMBA)
carcinogenesis, a model which is sensitive to the anticancer effects of the PA derivative 4-chlorophenylacetate (4-CPA).
Tumor induction by DMBA was not significantly different between the HTZ and HMZ mice, either in total tumor
development or in the type of cancers that arose. HMZ mice were then treated with 4-CPA as positive controls for the
anticancer effects of PA and to evaluate its possible effects on phenylalanine metabolism in PKU mice. 4-CPA had no effect
on the plasma concentrations of phenylalanine, phenylketones, or tyrosine. Surprisingly, the HMZ mice treated with 4-CPA
developed an unexplained neuromuscular syndrome which precluded its use in these animals as an anticancer agent.
Together, these studies support the use of PAH
enu2 mice as a model for studying human PKU. Chronically elevated levels of
PA in the PAH
enu2 mice were not protective against cancer.
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Introduction
About the time of the discovery of phenylketonuria (PKU) in
1934 [1], it was reported that patients with this disease excreted
abnormally high levels of phenylalanine metabolites in their urine.
These metabolites included a variety of compounds that normally
arise when phenylalanine is not broken down in the normal
fashion by the liver enzyme phenylalanine hydroxylase (PAH),
resulting in an alternate pathway of phenylalanine metabolism.
These observations led to the discovery of the causative factor of
PKU as being a lack of PAH activity due to one or more mutations
in the gene coding for this enzyme [2]. One of the compounds that
was shown to be markedly elevated in the urine of PKU subjects
was the phenylalanine metabolite phenylacetic acid [3]. This
compound, or the ionized form of the molecule, phenylacetate
(PA), is usually undetectable in plasma of normal individuals [4].
PA has been used for a long time in the treatment of conditions
associated with hyperammonemia (e.g. urea cycle disorders) [5,6].
This experience has indicated that millimolar blood serum levels of
PA can be achieved without significant adverse effects; prolonged
treatment with PA (up to 6 years) of children with inborn errors of
urea synthesis have not shown significant signs of toxicity [7]. This
lack of toxicity, along with studies demonstrating the anticancer
properties of PA derivatives against a variety of malignancies,
prompted intense investigation of these compounds in anticancer
applications [8–11]. To this end, our previous work demonstrated
that PA and its halide derivative 4-chlorophenylacetate (4-CPA),
can retard the growth of estrogen-dependent breast cancer cells in
vitro, and the development of breast cancer in an in vivo mouse
model [11,12]. Utilizing transgenic mice which exhibit chronically
elevated levels of estrogen in their mammary glands, these latter
studies showed that 4-CPA inhibited the development and growth
of estrogen-driven breast tumors. This antiestrogenic activity may
be due to the ability of PA and 4-CPA to interfere with estrogen
signaling through their direct binding to estrogen response element
regulatory sites in the promoters of target genes [13].
This information inexorably leads one to ask the following
question. Since PA is one of the metabolites of phenylalanine that
is elevated in individuals with PKU, is the cancer incidence/types/
cancer mortality different in this population of people? If so, PKU
may be ‘‘nature’s model’’ for assessing the anticancer properties of
this compound. To our knowledge, no such study has yet been
conducted. One reason for the dearth of information on this
subject may be that the oldest early-detected adults with PKU are
only now in their 409s, since national newborn screening did not
start until 1963 [14]. With a population that young, and the cancer
incidence among such a young group very low, coupled with the
small population size to begin with (total PKU population of all
ages of early-treated persons is probably less than 15,000
nationally), it may be difficult to discover anything definitive
about the protective effects of phenylacetate among these
individuals. A more interesting population to look at might be
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more cancer due to age. In addition, given their untreated PKU,
this population would likely have the highest amounts of
phenylacetate in their blood. However, for the most part these
untreated individuals are institutionalized, and tracking down
significant number would be difficult. Thus, although there are
some states (e.g. California and Minnesota) which maintain PKU
registries to facilitate acquisition of this data, it is clear that, at this
time, obtaining a definitive answer to these questions may not be
possible. As a result, we have tested our hypothesis that PKU may
protect against certain kinds of cancers by utilizing a well-
characterized PKU mouse model and a 7,12-dimethylbenzan-
thracene (DMBA)-induced tumor induction protocol. Our results
did not show a significant difference between the development of
tumors in PKU and control mice, and therefore do not support the
above hypothesis.
Results and Discussion
Phenylalanine, phenyketone, and CYP1B1 levels
Table 1 shows that phenylalanine and phenylketone levels,
known to be elevated in human PKU, were elevated in the PKU
homozygous PAH
eun2/eun2 (HMZ) mice and in the range reported
in the human disease [4,15]. Tyrosine was reduced in the HMZ
mice, also mimicking human PKU. Levels of phenylalanine and
tyrosine in the heterozygous PAH
enu2/wild mice (HTZ) were
similar to that seen in the wild-type BTBR strain and in normal
humans [15,16]. To our knowledge, plasma levels of these PKU-
related phenylketones in the HMZ mice have heretofore not been
reported. These analyses provide striking new evidence of the
remarkable similarities between murine PKU as represented in
this PAH
enu2 animal model and human PKU. Together with
reported genetic, neurological, and biochemical comparisons with
human PKU [16–18], our findings emphasize the physiologic
relevance of this mouse model for studying the human disease.
DMBA is a ‘‘pro-carcinogen’’ and must be metabolized to
produce the proximate carcinogenic metabolite 3,4-dihydrodiol
[19]. The main enzyme responsible for the catalytic conversion of
DMBA to an active carcinogen is the P450 enzyme CYP1B1 [19].
This conversion takes place mainly in the liver. CYP1A1, although
also contributing to the metabolism of DMBA, is thought to only
play a minor role in this process. Thus, potential differences in
tumor induction between HMZ and control animals could reflect
differences in the levels of these enzymes which would corre-
spondingly affect the carcinogenic potential of administered
DMBA. To address this potential complication in our study, we
measured the activity of these enzymes using ethoxyresorufin-O-
deethylase (EROD) as a surrogate substrate for DMBA [12]. This
compound is specifically catalyzed by CYP1A1 and CYP1B1 into
a fluorescent metabolite that can easily be measured by
spectrophotometry. As expected from previous mouse studies
[12,19], no activity was detected in mammary tissue from either
the control or HMZ mice (n=3). Both groups showed activity in
liver as follows: HTZ=7.062.0; HMZ=10.661.0 pmol resor-
ufin/min/per mg protein (p=0.18, not significant). Thus, there
was no significant difference between HTZ and HMZ mice in the
conversion of DMBA to its carcinogenic metabolite that might
otherwise have complicated the interpretation of possible differ-
ences in tumor induction between the groups.
Tumor development
To determine whether the HMZ mice show a reduced
incidence of tumor induction, we employed a protocol similar to
that previously used in our aromatase transgenic mouse study [12],
with the exception that slow release (90 day) MPA pellets were
added to the treatment to increase the incidence of tumors
induced [20]. MPA treatment was not necessary in the transgenic
mouse study due to the chronically elevated estrogen levels in the
mammary tissue of these mice [21]. For these experiments, 4 mice
in the HTZ group and 5 in the HMZ group expired before the
experiment was terminated and no tumors were discovered upon
necropsy. Therefore, these mice were not counted. As seen in
figure 1, tumors started to appear in both the HTZ and HMZ
groups between 12 and 16 weeks after the last dose of DMBA and
there were no significant differences in subsequent tumor
development between the groups at any time point (two-tailed
Fisher’s exact test). The mean tumor latency (6s.d.) for the HTZ
and HMZ mice was 22.9 (7.4) and 27.1 (6.9) weeks, respectively.
Using the log-rank test, the development of tumors between the
two groups is not significant (p-value of 0.37) which is consistent
with the results from the Fisher’s exact test. In contrast to our
previous study in which the overwhelming majority of tumors that
were induced in DMBA-treated aromatase transgenic mice were
breast cancers [12], a variety of tumor types developed in both the
HTZ and HMZ mice including ovarian, uterine, mammary
cancers, and lymphomas. These tumor types have previously been
reported to be induced by the DMBA/MPA treatment protocol
used in this study [22,23]. As shown in figure 2, there was no
significant difference in the distribution of these tumor types
between the two groups. However, it should be noted that the
number of mice used in these experiments was not sufficient for
detecting differences in the development of the specific tumor
types found in the study groups. Indeed, based on the tumors
showing the largest prevalence as well as the greatest difference in
occurrence between the HMZ and HTZ groups (mammary
tumors), at least 220 mice in each group would be required to
detect significant differences relating to the development of specific
tumor types (two-tailed Fisher’s exact test). We did not feel that
such an expanded study was warranted based on the present
findings.
These results do not support the hypothesis that chronically
elevated PA at serum levels seen in the HMZ mice (,13 mM) can
influence DMBA-mediated tumor induction. As such, these results
did not provide evidence that PKU can protect against cancer. A
Table 1. Amino Acid and Phenylketone Levels in Plasma of PKU Mice
a,b
Genotype Phenylacetate Phenyllactate Phenylpyruvate Tyrosine Phenylalanine
Heterozygous n.d.
c n.d. n.d. 86.3610.1 102.7614.8
Homozygous 12.561.7 16.162.5 51.068.1 35.265.2 1405.26115.9
aAll values are in mM/L and represent mean SEM of six mice in each group.
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potent suppression of 4-CPA on tumor induction in aromatase-
transgenic mice could be that tumors induced in the latter are
almost exclusively estrogen-driven [12,21]. In contrast, although
we did not determine the ER status of tumors arising in the present
work, similar induction protocols in a variety of mouse strains have
been shown to produce predominantly ER-negative (i.e. estrogen
independent) tumors [22–25]. Alternatively, both 4-CPA and PA
have been shown to be relatively weak antiestrogens and
concentrations of the compounds needed to effectively block the
action of ER in vitro were found to be in the mM range [26]. This
concentration range was achieved in the aromatase-transgenic
mouse experiments [12] while levels of PA detected in the HMZ
mice were only in the mM range.
When interpreting these results, we emphasize that effects of
certain carcinogens have been shown to be dependent on age, sex,
and animal strain in different mouse models. For example,
Horlings and Demant [27] demonstrated strain-specific differences
in lung tumor induction by ethylnitrosourea ENU while variations
between male and female mice in responses to protocols involving
ENU in promoting hepatocarcinogenesis have also been docu-
mented [28]. Carcinogenic studies of the parental strain of our
HMZ or HTZ mice (BTBR) have, to our knowledge, not been
reported, including that by ENU which was used in the creation of
this PKU model [17]. Thus, care should be taken not to ‘‘over
generalize’’ the results obtained here to PKU conditions of varied
genetic backgrounds.
Treatment of mice with 4-CPA
In PKU, there is defective hydroxylation of phenylalanine to
produce tyrosine. This condition results in reduced levels of
tyrosine metabolites such as thyroxin, melanin, and the dopamine
family of neurotransmitters [29,30]. The reduced levels of these
products can cause a variety of abnormalities associated with PKU
such as hypopigmentation and derangement of the dopaminergic
system although impaired cognitive function seems directly related
to the elevated phenylalanine levels. Physiologically, tyrosine is
converted to parahydroxyphenylpyruvate which is then further
converted by the enzyme dioxygenase to homogentisic acid [29].
Interestingly, one of the phenylketone products that is elevated in
PKU, phenylpyruvate (PPY), is structurally related to parahy-
droxyphenylpyruvate, the dioxygenase substrate for homogentisate
synthesis, and can act as a competitive inhibitor of this reaction
[31,32]. Thus, concentrations of PPY similar to that found in
plasma of some treated PKU patients have been shown to impair
tyrosine degradation through this pathway [33]. Since PA is a
metabolite of PPY, we tested the possibility that an increase in
plasma levels of 4-CPA in the HMZ mice could alter PPY levels
such as to inhibit tyrosine degradation and increase its plasma
concentration. In addition, treatment of mice with 4-CPA would
also serve as a positive control in order to substantiate that the
numerous metabolic abnormalities in the HMZ mice [16–18] do
not antagonize the anticancer properties of PA compounds. In our
Figure 1. Tumor development. Female HTZ and HMZ PAH
enu2 mice as indicated were subcutaneously implanted with a slow releasing MPA pellet
at approximately 5 weeks of age, then treated with DMBA p.o. (1 mg/mouse) approximately 2 weeks later. Mice were given a total of 4 treatments of
DMBA (one/week for 4 weeks). Tumor development in mice was assessed as described in Materials and Methods.
doi:10.1371/journal.pone.0004292.g001
Figure 2. Tumor types induced in the HTZ and HMZ mice.
doi:10.1371/journal.pone.0004292.g002
PKU and Cancer
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in the drinking water of an aromatase-transgenic mouse model of
breast cancer induction effectively inhibited tumor development
[12]. These studies also demonstrated that this treatment for many
months had no apparent adverse effects on the mice; there were no
significant differences between 4-CPA-consuming and control
groups in their water consumption, growth rate, social behavior,
or vitality.
Table 2 shows that while 4-CPA was not detected in the plasma
of untreated HTZ or HMZ mice, comparable levels of the
compound (,0.5 mM) were achieved in both groups following
2 weeks treatment by admixing 4-CPA in their drinking water.
This plasma concentration of 4-CPA was similar to that achieved
in our previous work [12,34]. Table 2 also shows that
administration of 4-CPA did not significantly affect the levels of
phenylketones, tryrosine, or phenylalanine in the plasma of the
HMZ or HTZ mice. Therefore, administration of PA derivatives
did not alter the metabolic degradation of tyrosine such as to result
in its increased plasma levels. However, in contrast to the complete
lack of side effects of 4-CPA seen in our previous study and in the
HTZ mice in the present work, the HMZ mice developed an
unexplained neuromuscular syndrome which became apparent
after the first week of 4-CPA treatment. This syndrome was
characterized by limb weakness, hypermetria, and ataxia, and was
progressive; by two weeks, weight lose of the mice was evident
which appeared to be due to difficulty in walking and feeding.
These adverse effects were only observed in the HMZ mice and
prevented our testing of the anticancer properties of 4-CPA in
these animals. Necropsy of the mice and histological analysis of the
limb musculature did not reveal any lesions or apparent
abnormalities. This interesting phenomenon was reversible; when
the 4-CPA-containing water was replaced by normal water, all
symptoms dissappeared within a few days. The characterization of
this interesting syndrome and the determination of its cause will be
the goal of future studies.
Materials and Methods
Maintenance and treatment of mice
All procedures were carried out in accordance with the National
Institutes of Health Guidelines on the Care and Use of Animals
and an animal study protocol approved by Emory University’s
Institutional Animal Care and Use Committee. Mice used in this
study were created in the BTBR strain by ENU germline
mutagenesis in the gene for phenylalanine hydroxylase (PAH)
which results in a loss of enzyme activity such that, in liver,
phenylalanine hydroxylase activity is minimal [16]. The homozy-
gous mutant BTBR-PAH
enu2 mouse has shown to be a remarkably
good model for human PKU. These animals show no residual
activity of the liver PAH along with very high plasma Phe levels.
Heterozygous PAH
enu2/wild (HTZ) and homozygous PAH
enu2/enu2
(HMZ) mice were produced by crossing HMZ fathers and HTZ
mothers. In our experiments, only female mice were utilized with
the HMZ experimental group and were compared with female
HTZ animals as the control group. Due to the well known
carcinogenic effects of ENU [27,28], we felt HTZ rather than
wild-type BTBR mice to be a better control group in order to best
isolate differences in tumor induction specifically due to the PKU
phenotype. Mice who are heterozygous for PAH
eun2/wild, like
humans who are heterozygous for the PKU genotype, have
plasma Phe levels that are similar to wild-type who carry no PAH
mutation [16–18]. Genotyping for the homozygous versus
heterozygous animals was not necessary since the homozygous
mice were easily discernable by their lightened (grayish) coat color
due to reduced melanin production.
To get reproducible tumor induction in the mice, we used a
combination of oral administration of 7,12-dimethylbenz[a]an-
thracene (DMBA) along with subcutaneous implantation of a slow
releasing (90-day) medroxyprogesterone acetate (MPA) pellet [20].
Briefly, Female HTZ or HMZ mice were subcutaneously
implanted with the MPA pellet at approximately 5 weeks of age,
then started DMBA treatment 2 weeks later. The DMBA (1.0 mg)
dissolved in 100 ml of corn oil was delivered via orogastric tube to
mildly anesthetized mice once per week for 4 weeks. One month
after the administration of DMBA, the mice were palpated for
tumors and weekly observations were continued up until
10 months after DMBA treatment. Mice were sacrificed shortly
after tumor identification, if noticeably ill, or at the termination of
the experiment. In selected mice, blood was obtained by cardiac
puncture into heparinized syringes and, after centrifugation, the
plasma was stored at 280 C until analysis by gas chromatogra-
phy/mass spectroscopy (GC/MS)[34].
Treatment of mice with 4-CPA was performed by continuous
intake of the compound in the animal’s drinking water at a
concentraion of 6 mg/ml as previously reported by our group
[12]. We have shown that this method of long-term 4-CPA
administration for many months has no adverse effects on the mice
and achieves a mean 4-CPA plasma concentration of ,0.8 mM.
Liver P450 enzyme activity and plasma protein analysis
Phenylalanine and metabolites in the plasma of HTZ and HMZ
mice were analyzed by an amino acid analyzer and GC/MS as
described [34]. Quantitation of 4-CPA was performed by gas
chromatography/mass spectroscopy (GC/MS) following ethylace-
tate/ether extraction of plasma deproteinized with 7% perchloric
acid, according to standard procedures. Specifically, 250 mLo f
Table 2. Amino Acid and Phenylketone Levels in Plasma of Treated Mice
a,b
Genotype Treatment Phenylacetate Phenyllactate Phenylpyruvate 4-CPA
c Tyrosine Phenylalanine
Heterozygous Untreated n.d.
d n.d. n.d. n.d. 98.069.1 111.3623.5
4-CPA
e n.d. n.d. n.d. 517.5638.0 107.768.8 107.369.4
Homozygous Untreated 12.061.4 12.362.6 44.967.5 n.d. 39.069.0 1453.765.2
4-CPA 18.160.5 15.862.4 36.262.2 428.6662.1 27.066.3 1051.3677.9
aAll values are in mM/L and represent mean6SEM of three mice in each group.
bDetermined by GC/MS as reported in our earlier work (34).
c4-chlorophenylacetate
dnot detected
e4-CPA added to drinking water for 2 weeks at a concentration of 6 ng/ml.
doi:10.1371/journal.pone.0004292.t002
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mixture was centrifuged and the supernatant used for the analysis.
The quantitation was accomplished by Selective Ion Monitoring
(SIM) using an external calibration curve obtained with a standard
undergoing the same extraction procedure as the samples.
Corrections for variations in the injections were made with an
internal standard (C24). The response was linear over a wide
range of concentrations (0–1700 nmoles).
To measure CYP1B1 activity, the ethoxyresorufin-O-deethylase
(EROD) assay was used [12,35]. Reactions were performed in a
total volume of 250 ml in microfuge tubes at 37uC at a final
substrate concentration of 4 mM. Microsomal protein (100–
250 mg) in storage buffer (10 mM Tris OAc, pH 7.4, 0.1 mM
EDTA, 23% glycerol) was added to 7-ethoxyresorufin dissolved in
DMSO and then diluted in double distilled water (final DMSO
concentration of 0.08% v/v). The reaction mixture was allowed to
equilibrate for 5 min at 37uC. Reactions were initiated by timed
additions of 50 mL NADPH (10 mM). After 10 min incubation at
37uC, the reaction was stopped by timed additions of 250 mLm lo f
ice-cold acetronitrile. EROD activity was determined by measur-
ing the fluorescence of resorufin at 545 nm (excitation) and
610 nm (emission) in a microplate reader. Resorufin standard
curves were used for the determination of the activities.
Assessment of tumors in mice
After the mice were sacrificed, necropsy and tumor evaluation
was performed by the Diagnostic Laboratory, Division of Animal
Resources, Emory University. The following tissue were collected
and examined for gross lesions or abnormalities: heart, lungs,
mammary glands, reproductive organs, liver, spleen, kidneys,
stomach, cecum, large and small intestine, brain, salivary glands,
thymus. Any suspicious tissue, tumors, and routinely mammary
glands (as being the main target of DMBA-induced tumors) were
dissected free from skin and processed for histology as previously
described [12]. Routine sections of tissues were prepared after
fixation in 10% neutral buffered formalin by embedding in
paraffin, sectioning at 5 mm, and staining with H&E. Tumors were
identified as described previously [12].
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